Among these molecules, angiopoietin 2 (Ang2) was targeted (clinical trial number NCT04342897), with the reasoning that circulating Ang2 levels correlate with increased pneumonic edema and mortality in patients with acute respiratory distress syndrome including COVID-19 [22,23,24,25]. This evidence concerns the gene ANGPT2 and acute respiratory distress syndrome.